Brain Metastases
Pipeline by Development Stage
Drug Modality Breakdown
Oncology is a $53.9B market in consolidation, dominated by a handful of megacap players with blockbuster franchises approaching patent expiration.
Key Trends
- Heavy patent cliff exposure (REVLIMID $3.9B LOE 2028, JAKAFI $1.9B LOE 2028)
- Kinase inhibitors and immunomodulatory agents dominate spend; limited diversification in top 10
- Clinical trial volume remains exceptionally high (29,145 trials) but concentration in Phase 1-2 signals early-stage pipeline challenges
Career Verdict
Strong near-term opportunity for R&D and medical affairs roles, but competitive landscape and patent cliff urgency favor specialists over generalists.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 34% | Launch | Stable | 15.0yr |
| 2 | FARXIGA (dapagliflozin) | AstraZeneca | $4.3B | 8% | Peak | Stable | 15.4yr |
| 3 | REVLIMID (lenalidomide) | Bristol Myers Squibb | $3.9B | 7% | LOE Approaching | Declining | 1.8yr |
| 4 | XTANDI (enzalutamide) | Astellas | $2.6B | 5% | Peak | Stable | 10.7yr |
| 5 | IMBRUVICA (ibrutinib) | AbbVie | $2.4B | 4% | Peak | Stable | 8.9yr |
Drug Class Breakdown
concentrated in single product
single dominant product
multi-product class, competitive
facing near-term patent cliff
prostate cancer specialty
niche hematologic oncology
near-term LOE exposure
Career Outlook
StableOncology remains a premium therapeutic area but faces structural headwinds: top 10 products account for >80% of spend, patent cliffs loom (REVLIMID 2028), and late-stage pipeline thinness suggests slower near-term growth. However, high trial volume and consolidation create demand for specialized expertise in regulatory, clinical operations, and lifecycle management. Pharma professionals with kinase inhibitor, immunomodulatory, or ADC experience are in highest demand.
Breaking In
Entry-level candidates should target CROs (Thermo Fisher, IQVIA), emerging biotech (BeiGene, BeOne), or contract manufacturing; oncology specialization requires demonstrated domain knowledge.
For Experienced Professionals
Experienced professionals should focus on lifecycle/patent strategy roles (high salary, low headcount) or pivot to emerging modalities (ADCs, bispecifics) to avoid commoditization in crowded kinase inhibitor space.
In-Demand Skills
Best For
Hiring Landscape
Oncology hiring is actively concentrated at Thermo Fisher Scientific (CRO/CDMO services, 559 jobs), AstraZeneca (208 jobs), and emerging biotech players like BeiGene (185 jobs). Commercial roles dominate (412 jobs, $136K avg) but R&D positions offer the highest salary premium ($199K avg, 347 roles). Patent cliff urgency is creating acute demand for regulatory, CMC, and lifecycle management expertise.
Top Hiring Companies
By Department
Strong near-term hiring momentum, especially in CRO/CDMO and emerging biotech; Medical Affairs offers highest compensation but limited headcount.
Competitive Landscape
22 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 21 trials with date data
Clinical Trials (21)
Total enrollment: 3,972 patients across 21 trials
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
Neoadjuvant vs. Intraoperative vs. Adjuvant Resection Cavity Radiotherapy of Brain Metastases
Study Assessing QBS72S For Treating Brain Metastases
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
Brigatinib Before Brain Irradiation Trial (B3i Trial)
Phase 2 Trial in Multiple Brain Metastases Outcomes With HA-SIB-WBRT
An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis
Pembrolizumab In Central Nervous System Metastases
STAR Cape+BKM120 MBC With Brain Met
RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases
Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer
Radiosensitization of Multiple Brain Metastases Using AGuIX Gadolinium Based Nanoparticles
Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases
Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases
Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors
Treatments for Brain Metastases With Poor Prognostic Factors
HyperArc Registry Study
The CyberChallenge Trial How Much is Too Much - What is the Role of Cyberknife Radiosurgery in Patients With Multiple Brain Metastases?
Supportive Care With or Without Repeated Whole Brain Radiotherapy in Patients With Recurrent Brain Metastases
Related Jobs in Oncology
Senior Virology Care Specialist
Sr. Biosample Manager
Oncology Account Manager, North Central
(Assoc.) Director, Clinical Development Scientist-Urologic Oncology
(Sr.) Medical Director, Oncology
Oncology Home Infusion Nurse (RN)
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.